December 13, 2016
CTI Clinical Trial & Consulting Services To Present at National Academy of Science Committee on Organ Donor Intervention Research
FOR IMMEDIATE RELEASE [Cincinnati, OH ~ December 13, 2016]
CTI Clinical Trial and Consulting Services (CTI), a multi-national, privately held, full-service contract research organization will participate at the National Academy of Science Committee on December 14, 2016 in Washington DC. CTI's Founder and Chief Executive Officer, Timothy J. Schroeder, will present on future approaches to organ donor intervention research study design.
This ad-hoc group will examine the ethical policy, regulatory and operational issues relevant to the conduct of research involving deceased organ donors. The committee will examine the gaps, barriers, and opportunities for clinical research including deceased donors that aims to increase the quality and quantity of donated organs available for transplant, particular attention to interventions administered to the donor and thus potentially affecting all of the donor's organs.
"I am very excited to participate in this critically important meeting," according to Schroeder. "CTI has been involved in transplant research since our inception 18 years ago and is keenly aware of the impact of increasing the number and quality of organs for transplantation. While many therapeutics and diagnostics have been and continue to be developed for the transplant recipient, there is a dearth of clinical research programs currently ongoing involving the donor. We look forward to helping to overcome the many barriers in this setting."
About CTI Clinical Trial and Consulting Services
CTI Clinical Trial and Consulting Services is a global, privately held, full-service contract research organization (CRO), delivering a complete spectrum of clinical trial and consulting services throughout the lifecycle of development, from concept to commercialization. CTI’s focused therapeutic approach provides pharmaceutical, biotechnology, and medical device firms with clinical and disease area expertise in rare diseases, regenerative medicine/gene therapy, immunology, transplantation, nephrology, hematology/oncology, neurology, infectious diseases, hepatology, cardiopulmonary, and pediatric populations. CTI also offers a fully integrated multi-specialty clinical research site that conducts phase I-IV trials. CTI has a passion for helping life-changing therapies succeed in chronically and critically ill patient populations. With clinical trial experience across 6 continents, CTI partners with research sites, patients, and sponsors to fulfill unmet medical needs. CTI is headquartered in Cincinnati, OH, with operations across North America, Europe, Latin America, and Asia-Pacific. For more information visit www.ctifacts.com
About National Academies of Sciences, Engineering and Medicine
The National Academies of Sciences, Engineering, and Medicine are private, nonprofit institutions that provide expert advice on some of the most pressing challenges facing the nation and the world. Our work helps shape sound policies, inform public opinion, and advance the pursuit of science, engineering, and medicine. For more information visit http://www.nationalacademies.org